Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
View Patent ↗The present disclosure describes bicyclic heteroaromatic carboxamide derivatives, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
1. A compound of any one of the following Formulae (XVI), (XX), and (XXIV):
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is H;
R 2 is H, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, CN, OR a2 , SR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , OC(O)R b2 , OC(O)NR c2 R d2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)NR c2 R d2 , NR c2 C(O)OR a2 , C(═NR e2 )NR c2 R d2 , NR c2 C(═NR e2 )NR c2 R d2 , S(O)R b2 , S(O)NR c2 R d2 , S(O) 2 R b2 , NR c2 S(O) 2 R b2 or S(O) 2 NR c2 R d2 ;
R 4 is H or halogen;
R 5 is H or halogen;
each R 7 is independently, at each occurrence, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, Cy 6 , -L 6 -Cy 6 , CN, OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , NR c3 C(O)R b3 , NR c3 C(O)NR c3 R d3 , NR c3 C(O)OR a3 , C(═NR e3 )NR c3 R d3 , NR c3 C(═NR e3 )NR c3 R d3 , S(O)R b3 , S(O)NR c3 R d3 , S(O) 2 R b3 , NR c3 S(O) 2 R b3 or S(O) 2 NR c3 R d3 ,
wherein said C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl forming R 7 are each independently unsubstituted or substituted with 1, 2 or 3 substituents independently selected from halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, CN, OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , NR c3 R d3 , NR c3 C(O)R b3 , NR c3 C(O)NR c3 R d3 , NR c3 C(O)OR a3 , C(═NR e3 )NR c3 R d3 , NR c3 C(═NR e3 )NR c3 R d3 , S(O)R b3 , S(O)NR c3 R d3 , S(O) 2 R b3 and S(O) 2 NR c3 R d3 ;
Cy 6 is unsubstituted or substituted C 6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C 3-6 cycloalkyl, or unsubstituted or substituted 4-12 membered heterocycloalkyl,
wherein the substituted C 6-10 aryl, 5-10 membered heteroaryl, C 3-6 cycloalkyl or 4-12 membered heterocycloalkyl forming Cy 6 is substituted with 1, 2, 3, 4 or 5 substituents each independently selected from halogen, R Cy6 , C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, CN, OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , NR c3 R d3 , NR c3 C(O)R b3 , NR c3 C(O)NR c3 R d3 , NR c3 C(O)OR a3 , C(═NR e3 )NR c3 R d3 , NR c3 C(═NR e3 )NR c3 R d3 , S(O)R b3 , S(O)NR c3 R d3 , S(O) 2 R b3 , NR c3 S(O) 2 R b3 and S(O) 2 NR c3 R d3 ,wherein each R Cy6 is C 1-6 alkyl, each of which is independently unsubstituted or substituted by 1, 2 or 3 substituents independently selected from halogen, CN, OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , NR c3 R d3 , NR c3 C(O)R b3 , NR c3 C(O)NR c3 R d3 , NR c3 C(O)OR a3 , C(═NR e3 )NR c3 R d3 , NR c3 C(═NR e3 )NR c3 R d3 , S(O)R b3 , S(O)NR c3 R d3 , S(O) 2 R b3 NR c3 S(O) 2 R b3 and S(O) 2 NR c3 R d3 ; or
alternatively, the substituted C 6-10 aryl, 5-10 membered heteroaryl, C 3-6 cycloalkyl or 4-12 membered heterocycloalkyl forming Cy 6 is substituted with unsubstituted C 6-10 aryl or C 6-10 aryl substituted by 1, 2, 3, 4 or 5 substituents independently selected from halogen, CN, OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , NR c3 R d3 , NR c3 C(O)R b3 , NR c3 C(O)NR c3 R d3 , NR c3 C(O)OR a3 , C(═NR e3 )NR c3 R d3 , NR c3 C(═NR e3 )NR c3 R d3 , S(O)R b3 , S(O)NR c3 R d3 , S(O) 2 R b3 NR c3 S(O) 2 R b3 and S(O) 2 NR c3 R d3 ;
L 6 is unsubstituted C 1-6 alkylene or C 1-6 alkylene substituted with 1, 2 or 3 substituents independently selected from F, Cl, CN, OH, O(C 1-6 alkyl), NH 2 , NH(C 1-6 alkyl) and N(C 1-6 alkyl) 2 ;
R a2 , R b2 , R c2 and R d2 are each independently selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10membered heterocycloalkyl, C 6-10 aryl-C 1-3 alkyl, 5-10 membered heteroaryl-C 1-3 alkyl, C 3-7 cycloalkyl-C 1-3 alkyl and 4-10 membered heterocycloalkyl-C 1-3 alkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-3 alkyl, 5-10 membered heteroaryl-C 1-3 alkyl, C 3-7 cycloalkyl-C 1-3 alkyl and 4-10 membered heterocycloalkyl-C 1-3 alkyl forming R a2 , R b2 , R c2 and R d2 are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from C 1-6 alkyl, halo, CN, OR a5 , SR a5 , C(O)R b5 , C(O)NR c5 R d5 , C(O)OR a5 , OC(O)R b5 , OC(O)NR c5 R d5 , NR c5 R d5 , NR c5 C(O)R b5 , NR c5 C(O)NR c5 R d5 , NR c5 C(O)OR a5 , C(═NR e5 )NR c5 R d5 , NR c5 C(═NR e5 )NR c5 R d5 , S(O)R b5 , S(O)NR c5 R d5 , S(O) 2 R b5 , NR c5 S(O) 2 R b5 and S(O) 2 NR c5 R d5 ;
or R c2 and R d2 attached to the same N atom, together with the N atom to which they are both attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or 5-membered heteroaryl group, each optionally substituted with 1, 2 or 3 substituents independently selected from C 1-6 alkyl, halo, CN, OR a5 , SR a5 , C(O)R b5 , C(O)NR c5 R d5 , C(O)OR a5 , OC(O)R b5 , OC(O)NR c5 R d5 , NR c5 R d5 , NR c5 C(O)R b5 , NR c5 , C(O)NR c5 R d5 , NR c5 C(O)OR a5 , C(═NR e5 )NR c5 R d5 , NR c5 C(═NR e5 )NR c5 R d5 S(O)R b5 , S(O)NR c5 R d5 , S(O) 2 R b5 , NR c5 S(O) 2 R b5 and S(O) 2 NR c5 R d5 ;
R a3 , R b3 , R c3 and R d3 are each independently selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-3 alkyl, 5-10 membered heteroaryl-C 1-3 alkyl, C 3-7 cycloalkyl-C 1-3 alkyl and 4-10 membered heterocycloalkyl-C 1-3 alkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl-C 3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-3 alkyl, 5-10 membered heteroaryl-C 1-3 alkyl, C 3-7 cycloalkyl-C 1-3 alkyl and 4-10 membered heterocycloalkyl-C 1-3 alkyl forming R a3 , R b3 , R c3 and R d3 are each optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from C 1-6 alkyl, halo, CN, OR a6 , SR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)OR a6 , OC(O)R b6 , OC(O)NR c6 R d6 , NR c6 R d6 , NR c6 C(O)R b6 , NR c6 C(O)NR c6 R d6 , NR c6 C(O)OR a6 , C(═NR e6 )NR c6 R d6 , NR c6 C(═NR e6 )NR c6 R d6 , S(O)R b6 , S(O)NR c6 R d6 , S(O) 2 R b6 , NR c6 S(O) 2 R b6 and S(O) 2 NR c6 R d6 ;
or R c3 and R d3 attached to the same N atom, together with the N atom to which they are both attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or 5-membered heteroaryl group, each optionally substituted with 1, 2 or 3 substituents independently selected from C 1-6 alkyl, halo, CN, OR a6 , SR a6 , C(O)R b6 , C(O)NR c6 R d6 , C(O)OR a6 , OC(O)R b6 , OC(O)NR c6 R d6 , NR c6 R d6 , NR c6 C(O)R b6 NR c6 C(O)NR c6 R d6 , NR c6 C(O)OR a6 , C(═NR e6 )NR c6 R d6 , NR c6 C(═NR e6 )NR c6 R d6 , S(O)R b6 , S(O)NR c6 R d6 , S(O) 2 R b6 , NR c6 S(O) 2 R b6 and S(O) 2 NR c6 R d6 ;
R a5 , R b5 , R c5 and R d5 are each independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-3 alkyl, 5-6 membered heteroaryl-C 1-3 alkyl, C 3-7 cycloalkyl-C 1-3 alkyl and 4-7 membered heterocycloalkyl-C 1-3 alkyl, wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-3 alkyl, 5-6 membered heteroaryl-C 1-3 alkyl, C 3-7 cycloalkyl-C 1-3 alkyl and 4-7 membered heterocycloalkyl-C 1-3 alkyl forming R a5 , R b5 , R c5 and R d5 are each optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, NH(C 1-6 alkyl), N(C 1-6 alkyl) 2 , halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl and C 1-6 haloalkoxy;
or R c5 and R d5 attached to the same N atom, together with the N atom to which they are both attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or 5-membered heteroaryl group, each optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, NH(C 1-6 alkyl), N(C 1-6 alkyl) 2 , halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl and C 1-6 haloalkoxy;
R a6 , R b6 , R c6 and R d6 are each independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-3 alkyl, 5-6 membered heteroaryl-C 1-3 alkyl, C 3-7 cycloalkyl-C 1-3 alkyl and 4-7 membered heterocycloalkyl-C 1-3 alkyl, wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-3 alkyl, 5-6 membered heteroaryl-C 1-3 alkyl, C 3-7 cycloalkyl-C 1-3 alkyl and 4-7 membered heterocycloalkyl-C 1-3 alkyl forming R a6 , R b6 , R c6 and R d6 are each optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, NH(C 1-6 alkyl), N(C 1-6 alkyl) 2 , halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl and C 1-6 haloalkoxy;
or R c6 and R d6 attached to the same N atom, together with the N atom to which they are both attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or 5-membered heteroaryl group, each optionally substituted with 1, 2 or 3 substituents independently selected from OH, CN, amino, NH(C 1-6 alkyl), N(C 1-6 alkyl) 2 , halo, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl and C 1-6 haloalkoxy; and
R e2 , R e3 , R e5 and R e6 are each, independently, H, CN or NO 2 .
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein
Cy 6 is unsubstituted or substituted C 6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C 3-6 cycloalkyl, or unsubstituted or substituted 4-12 membered heterocycloalkyl,
wherein the substituted C 6-10 aryl, 5-10 membered heteroaryl, C 3-6 cycloalkyl or 4-12 membered heterocycloalkyl forming Cy 6 is substituted with 1, 2, 3, 4 or 5 substituents each independently selected from halogen, R Cy6 , C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, CN, OR a3 , SR a3 , C(O)R b3 , C(O)NR c3 R d3 , C(O)OR a3 , OC(O)R b3 , OC(O)NR c3 R d3 , NR c3 R d3 , NR c3 C(O)R b3 , NR c3 C(O)NR c3 R d3 , NR c3 C(O)OR a3 , C(═NR e3 )NR c3 R d3 , NR c3 C(═NR e3 )NR c3 R d3 , S(O)R b3 , S(O)NR c3 R d3 , S(O) 2 R b3 , NR c3 S(O) 2 R b3 and S(O) 2 NR c3 R d3 .
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is H and R 2 is H.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is H.
5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is halogen.
6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is H.
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is halogen.
8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 4 and R 5 are each H.
9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
each R 7 is independently, C 1-6 alkyl, Cy 6 , or -L-Cy 6 ;
Cy 6 is unsubstituted or substituted C 6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C 3-6 cycloalkyl, or unsubstituted or substituted 4-12 membered heterocycloalkyl,
wherein the substituted C 6-10 aryl, 5-10 membered heteroaryl, C 3-6 cycloalkyl or 4-12 membered heterocycloalkyl forming Cy 6 is substituted with 1, 2 or 3 substituents each independently selected from halogen, R cy6 , CN, OR a3 , and NR c3 R d3 ,
alternatively, the substituted C 6-10 aryl, 5-10 membered heteroaryl, C 3-6 cycloalkyl or 4-12 membered heterocycloalkyl forming Cy 6 is substituted with unsubstituted C 6-10 aryl;
wherein each R Cy6 is C 1-6 alkyl, each of which is independently unsubstituted or substituted by 1, 2 or 3 substituents independently selected from halogen, CN, and OR a3 ; and
wherein R c3 and R d3 attached to the same N atom, together with the N atom to which they are both attached, form a 6-membered heterocycloalkyl group or 5-membered heteroaryl group, each optionally substituted with 1 or 2 substituents independently selected from C 1-6 alkyl, halo, CN, and OR a6 .
10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
each R 7 is independently, C 1-6 alkyl, Cy 6 , or -L-Cy 6 ;
Cy 6 is unsubstituted or substituted C 6-10 aryl, unsubstituted or substituted 5-10 membered heteroaryl, unsubstituted or substituted C 3-6 cycloalkyl or unsubstituted or substituted 4-12 membered heterocycloalkyl,
wherein the substituted C 6-10 aryl, 5-10 membered heteroaryl, C 3-6 cycloalkyl or 4-12 membered heterocycloalkyl forming Cy 6 is substituted with 1, 2 or 3 substituents each independently selected from halogen, R Cy6 , CN, OR a3 , and NR c3 R d3 ,
alternatively, the substituted C 6-10 aryl, 5-10 membered heteroaryl, C 3-6 cycloalkyl or 4-12 membered heterocycloalkyl forming Cy 6 is substituted with unsubstituted C 6-10 aryl;
wherein each R Cy6 is C 1-6 alkyl, each of which is independently unsubstituted or substituted by 1, 2 or 3 substituents independently selected from halogen, CN, and OR a3 ; and
wherein R c3 and R d3 attached to the same N atom, together with the N atom to which they are both attached, form a 6-membered heterocycloalkyl group optionally substituted with 1 or 2 substituents independently selected from C 1-6 alkyl, halo, CN, and OR a6 .
11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is C 1-6 alkyl.
12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is methyl, ethyl, propyl, or isopropyl.
13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is Cy 6 or -L-Cy 6 .
14. The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein R 7 is Cy 6 .
15. The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein R 7 is -L-Cy 6 .
16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 unsubstituted or substituted C 6-10 aryl.
17. The compound of claim 16 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is unsubstituted or substituted phenyl.
18. The compound of claim 17 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is phenyl substituted with 1, 2 or 3 substituents.
19. The compound of claim 18 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is phenyl substituted with 1, 2 or 3 substituents each independently selected from halogen and OR a3 .
20. The compound of claim 19 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is 2-fluorophenyl, 2,6-difluorophenyl, 2,6-difluoro-3-methoxyphenyl, or 2,6-difluoro-4-methoxyphenyl.
21. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is unsubstituted or substituted 5-10 membered heteroaryl.
22. The compound of claim 21 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is unsubstituted or substituted 5-10 membered heteroaryl, the ring atoms of which consist of carbon atoms and 1 or 2 heteroatoms independently selected from O and N.
23. The compound of claim 21 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is unsubstituted or substituted 5-10 membered heteroaryl, the ring atoms of which consist of carbon atoms and 1 or 2 nitrogen atoms.
24. The compound of claim 21 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is unsubstituted or substituted 5-10 membered heteroaryl, the ring atoms of which consist of carbon atoms, 1 oxygen atom and 1 nitrogen atom.
25. The compound of claim 21 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is unsubstituted or substituted pyridinyl, isoxazolyl, pyrazolyl or pyrimidinyl.
26. The compound of claim 21 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is unsubstituted or substituted pyridin-3-yl, pyridin-4-yl, isoxazol-4-yl, 1H-pyrazol-4-yl, or pyrimidin-5-yl.
27. The compound of claim 26 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is pyridin-3-yl, pyridin-4-yl, isoxazol-4-yl, 1H-pyrazol-4-yl, or pyrimidin-5-yl, each of which is unsubstituted or substituted with one or two substituents selected from halogen, C 1-6 alkyl, CN, OR a3 , and NR c3 R d3 .
28. The compound of claim 27 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is 6-morpholinopyridin-3-yl, 6-methoxypyridin-3-yl, 5-methoxypyridin-3-yl, 5-cyanopyridin-3-yl, 2,6-difluoropyridin-4-yl, isoxazol-4-yl, 1-methyl-1H-pyrazol-4-yl, or pyrimidin-5-yl.
29. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is unsubstituted or substituted C 3-6 cycloalkyl.
30. The compound of claim 29 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is unsubstituted cyclopropyl.
31. The compound of claim 29 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is cyclopropyl substituted by phenyl.
32. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is unsubstituted or substituted 4-12 membered heterocycloalkyl.
33. The compound of claim 32 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is 4-12 membered heterocycloalkyl which is unsubstituted or substituted with one or two C 1-6 alkyl groups.
34. The compound of claim 32 , or a pharmaceutically acceptable salt thereof, wherein each Cy 6 is 4-tetrahydropyranyl, 3-tetrahydrofuryl, 3,4-dihydro-2H-pyran-5-yl, or 1-methylpiperidin-4-yl.
35. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each L 6 is unsubstituted C 1-6 alkylene or C 1-6 alkylene substituted with 1, 2, or 3 substituents independently selected from F, Cl, CN, OH, and O(C 1-6 alkyl).
36. The compound of claim 35 , or a pharmaceutically acceptable salt thereof, wherein each L 6 is unsubstituted C 1-6 alkylene.
37. The compound of claim 36 , or a pharmaceutically acceptable salt thereof, wherein each L 6 is CH 2.
38. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 7 is methyl, ethyl, propyl, isopropyl, cyclopropyl, phenyl, 2-fluorophenyl, 2,6-difluorophenyl, 2,6-difluoro-3-methoxyphenyl, 2,6-difluoro-4-methoxyphenyl, benzyl, 2-fluorobenzyl, 2,6-difluorobenzyl, 2,6-difluoro-3-methoxybenzyl, 2,6-difluoro-4-methoxybenzyl, pyridin-3-yl, pyridin-4-yl, isoxazol-4-yl, 1H-pyrazol-4-yl, pyrimidin-5-yl, 6-morpholinopyridin-3-yl, 6-methoxypyridin-3-yl, 5-methoxypyridin-3-yl, 5-cyanopyridin-3-yl, 2,6-difluoropyridin-4-yl, isoxazol-4-yl, 1-methyl-1H-pyrazol-4-yl, pyrimidin-5-yl, 4-tetrahydropyranyl, 3-tetrahydrofuryl, 3,4-dihydro-2H-pyran-5-yl, or 1-methylpiperidin-4-yl.
39. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R a2 , R b2 , R c2 , R d2 , R a3 , R b3 , R c3 , R d3 , R a5 , R b5 , R c5 , R d5 , R a6 , R b6 , R c6 and R d6 are each independently selected from H and C 1-6 alkyl.
40. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R e2 , R e3 , R e5 and R e6 are each independently selected from H and C 1-6 alkyl.
41. The compound of claim 1 selected from the following compounds, or a pharmaceutically acceptable salt thereof:
N-(4-((3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl)pyridin-3-yl)-2-propylthieno[3,2-b]pyridine-5 -carboxamide;
N-(4-((3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl)pyridin-3-yl)-2-isopropylthieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(2,6-difluorophenyl)thieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3R,4R,5S)-3-amino-4-hydroxy-5- methylpiperidin-1-yl)pyridin-3-yl)-2-(2-fluorophenyl)thieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl)pyridin-3-yl)-2-benzylthieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(6-methoxypyridin-3-yl)thieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(6-morpholinopyridin-3-yl)thieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(2,6-difluoro-4-methoxyphenyl)thieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl)pyridin-3-yl)-2-phenylthieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl)pyridin-3-yl)-2-cyclopropylthieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(1-methyl-1H-pyrazol-4-yl)thieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl)pyridin-3-yl)-2-methylthieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-propylthieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-isopropylthieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(2,6-difluorophenyl)thieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(2-fluorophenyl)thieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-benzylthieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(6-methoxypyridin-3-yl)thieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(6-morpholinopyridin-3-yl)thieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(2,6-difluoro-4-methoxyphenyl)thieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-phenylthieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-cyclopropylthieno[3,2-b]pyridine-5-carboxamide;
N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-(1-methyl-1H -pyrazol-4-yl)thieno[3,2-b]pyridine-5-carboxamide; and
N-(4-((3S,5R)-3-amino-5-methylpiperidin-1-yl)pyridin-3-yl)-2-methylthieno[3,2-b]pyridine-5-carboxamide.
42. The compound of claim 1 which is N-(4-((3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl)pyridin-3-yl)-2-ethylthieno[3,2-b]pyridine-5-carboxamide, or a pharmaceutically acceptable salt thereof.
43. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.